Research Advances of metronomic Chemotherapy in Non-small Cell Lung Cancer
10.3760/cma.j.issn.1008-6315.2020.02.020
- VernacularTitle:节拍化疗在晚期非小细胞肺癌中的研究进展
- Author:
Yue YU
1
;
Baogang LIU
Author Information
1. 哈尔滨医科大学附属肿瘤医院呼吸肺病内科 150000
- From:
Clinical Medicine of China
2020;36(2):186-189
- CountryChina
- Language:Chinese
-
Abstract:
Advanced non-small cell lung cancer is one of the most difficult malignant tumors in the world. At present, chemotherapy is the most common treatment for NSCLC. However, traditional chemotherapy can kill tumor cells as well as normal cells. In order to solve this problem, metronomic chemotherapy came into being. It can inhibit tumor angiogenesis and tumor growth through a continuous high-frequency, low-dose administration. Metronomic chemotherapy can effectively control the disease progression of advanced NSCLC patients, delay their life span and improve their quality of life. Therefore, metronomic chemotherapy has become an effective treatment for advanced non-small cell lung cancer.
